Camena Bioscience secures £7.8 million Series A investment led by Mercia
Camena Bioscience, a Cambridge-based company which provides synthetic genes to the pharmaceutical and biotechnology industries, has completed a £7.8m ($10m) Series A funding round led by Mercia Ventures. The new funding will be used to scale operations and continue development of its pioneering DNA synthesis platform, gSynth.
Camena is the first company to offer this unique and highly accurate enzyme-based DNA synthesis technology. It has already signed commercial agreements with leading biotech and pharmaceutical companies and secured a multi-million pound revenue stream.
Synthetic genes are widely used by researchers to understand the mechanisms of disease, and in the drug discovery process to combat them. However traditional DNA synthesis methods developed in the 1980s remain problematic in terms of cost, time and accuracy, particularly when creating long or complex sequences of genes. Camena’s technology overcomes these limitations by using a wholly novel enzymatic technology to accurately produce synthetic DNA.
Camena was co-founded by CEO Steve Harvey PhD, a leader in genomics research, and CSO Derek Stemple PhD, a world-renowned molecular biologist. Derek was previously a co-founder of TwistDX which was acquired by Alere (now a part of Abbott) in 2010.
Steve Harvey, CEO, commented:
“We are delighted to have closed this latest round of funding with Mercia, which provides further validation of Camena’s approach. The ability to read, write and manipulate DNA is the foundation of the synthetic biology value chain, yet developments in DNA synthesis have not kept pace with DNA sequencing and editing capabilities. Camena’s gSynth platform is revolutionising the DNA synthesis market by unlocking access to genes and accelerating discovery pipelines. As the focus on sustainability and supply-chain security become more acute, Camena is leading the way with a green synthesis technology and is already well positioned to serve this burgeoning market. The invention of next-generation DNA sequencing technologies transformed our ability to ‘read’ DNA. Our goal is to enable our customers to ‘write’ DNA with the same confidence and ease.”
Mercia was investing from its Northern Venture Capital Trusts (VCTs). Lee Lindley from Mercia’s investment team, who has joined the Camena board, commented:
“The market for synthetic genes is growing rapidly but a lot of demand is for complex genes which are extremely difficult to produce accurately. Camena can provide a solution that no other provider can deliver. The development of the company’s gSynth technology is a game changer that could unlock a much bigger global market. We’re really excited to be supporting Camena on its next stage of growth.”
Experienced biotechnology inventor and executive Aditya Rajagopal, founder of diagnostics company ChromaCode Inc and co-founder of Esperto Medical, has also joined the board.
ENDS
Notes to editors:
About the new board members
Lee Lindley has nearly 10 years of corporate finance and investing experience; he also holds a BA in Natural Sciences from the University of Cambridge and a Masters in Research Methods from the University of Manchester
Aditya Rajagopal is the founder and CTO of ChromaCode, Inc. a commercial stage diagnostics company focused on developing highly scalable and affordable cancer tests. He is also the co-founder and Executive Chairman of Esperto Medical, a venture-backed company building non-invasive vital sign monitors.
“We’ve spent the past couple decades building tools, like next-generation DNA sequencers, to observe biology”, said Aditya. “Going forward, technologies like Camena’s will help us engineer biology.”
Press contacts
Alison Dwyer
Head of Marketing & Communications
Mercia Asset Management PLC
+44 (0) 7464 480 137
Pauline Rawsterne
PR Agent
Turquoise PR
+44 (0) 161 860 6063
+44 (0) 780 163 9816
About Mercia Asset Management PLC
Mercia is a proactive venture capital investor that aims to be a start-up’s first-choice partner for growth. Mercia currently has c. £1.4 billion of assets under management and has invested in a portfolio of over 400 start-ups from pre-seed to Series B and beyond. Mercia has nine offices in the UK and over 60 investment professionals, all drawing on their experiences as founders, PhD scientists, software engineers, corporate financiers and management consultants to help our partner companies successfully achieve their ambitions.
Mercia’s venture funds sit alongside the Mercia Group’s wider private equity, debt and proprietary balance sheet capital, in order to provide a ‘Complete Connected Capital’ solution for our portfolio. Mercia Asset Management PLC is quoted on AIM with the epic “MERC”.
Mercia Asset Management PLC is quoted on AIM with the epic “MERC” and includes the following wholly owned subsidiaries –
- Mercia Fund Management Limited is authorised and regulated by the FCA under firm reference number 524856
- Enterprise Ventures Limited is authorised and regulated by the FCA under firm reference number 183363
- EV Business Loans Limited is authorised and regulated by the FCA under firm reference number 443560
